NASDAQ:MRTX - Mirati Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $217.92
Forecasted Upside: 33.67 %
Number of Analysts: 16
Breakdown:
1 Sell Ratings
4 Hold Ratings
11 Buy Ratings
0 Strong Buy Ratings

^$163.03 As of 06/23/2021 01:00 AM ET

▼ -2.04 (-1.24%)

1 month | 3 months | 12 months

Get New Mirati Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for MRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRTX

^$217.92

▲ +33.67% Upside Potential

This price target is based on 16 analysts offering 12 month price targets for Mirati Therapeutics in the last 3 months. The average price target is $217.92, with a high forecast of $285.00 and a low forecast of $160.00. The average price target represents a 33.67% upside from the last price of $163.03.

Current Consensus is Buy

The current consensus among 16 contributing investment analysts is to buy stock in Mirati Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
10 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

12/31/2019

0 strong buy ratings
10 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

3/30/2020

0 strong buy ratings
8 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

6/28/2020

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

9/26/2020

0 strong buy ratings
12 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

12/25/2020

0 strong buy ratings
11 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

3/25/2021

0 strong buy ratings
10 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

5/24/2021

0 strong buy ratings
11 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

6/23/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/4/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Upgrade	Neutral ➝ Buy		Low
6/4/2021	Citigroup	Upgrade	Neutral ➝ Buy		Low
5/24/2021	Oppenheimer	Reiterated Rating	Outperform ➝ Market Perform	$245.00 ➝ $160.00	Medium
5/17/2021	Oppenheimer	Downgrade	Outperform ➝ Market Perform	$245.00 ➝ $160.00	Low
5/10/2021	HC Wainwright	Lower Price Target	Buy	$255.00 ➝ $251.00	Medium
5/10/2021	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$208.00 ➝ $196.00	Medium
3/1/2021	Oppenheimer	Lower Price Target	Outperform	$260.00 ➝ $255.00	Low
3/1/2021	HC Wainwright	Lower Price Target	Buy	$257.00 ➝ $255.00	Low
1/15/2021	HC Wainwright	Lower Price Target	Buy	$265.00 ➝ $257.00	Low
12/16/2020	Credit Suisse Group	Boost Price Target	Outperform	$225.00 ➝ $285.00	Low
12/8/2020	Evercore ISI	Initiated Coverage	Outperform		Medium
12/8/2020	JMP Securities	Initiated Coverage	Market Perform		Medium
11/17/2020	Bank of America	Downgrade	Neutral ➝ Underperform	$196.00	Low
11/10/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$206.00 ➝ $208.00	Low
11/10/2020	Guggenheim	Downgrade	Buy ➝ Neutral	$230.00	Low
11/9/2020	HC Wainwright	Boost Price Target	Buy	$233.00 ➝ $265.00	Medium
11/5/2020	Oppenheimer	Boost Price Target		$225.00 ➝ $260.00	Low
11/5/2020	Piper Sandler	Boost Price Target	Overweight	$210.00 ➝ $260.00	Medium
11/2/2020	HC Wainwright	Lower Price Target	Buy	$238.00 ➝ $233.00	Low
10/29/2020	Barclays	Boost Price Target	Overweight	$143.00 ➝ $244.00	High
10/27/2020	Credit Suisse Group	Boost Price Target	Outperform	$190.00 ➝ $225.00	High
10/26/2020	Oppenheimer	Boost Price Target	Outperform	$190.00 ➝ $225.00	High
10/26/2020	SVB Leerink	Boost Price Target	Outperform	$134.00 ➝ $195.00	High
10/26/2020	The Goldman Sachs Group	Boost Price Target	Buy	$152.00 ➝ $267.00	High
10/26/2020	HC Wainwright	Boost Price Target	Buy	$222.00 ➝ $238.00	High
10/26/2020	Piper Sandler	Boost Price Target	Overweight	$170.00 ➝ $210.00	High
10/21/2020	BMO Capital Markets	Boost Price Target	Market Perform	$101.00 ➝ $176.00	High
10/16/2020	HC Wainwright	Boost Price Target	Buy	$185.00 ➝ $222.00	High
10/8/2020	CSFB	Boost Price Target	Outperform	$140.00 ➝ $190.00	Medium
10/8/2020	Credit Suisse Group	Boost Price Target	Outperform	$140.00 ➝ $190.00	Medium
9/28/2020	Bank of America	Initiated Coverage	Neutral	$172.00	Low
9/21/2020	Oppenheimer	Boost Price Target	Outperform	$133.00 ➝ $190.00	Low
9/21/2020	Piper Sandler	Boost Price Target	Overweight	$145.00 ➝ $170.00	Low
9/18/2020	Citigroup	Downgrade	Buy ➝ Neutral	$127.00 ➝ $183.00	Medium
9/17/2020	HC Wainwright	Boost Price Target	Buy	$163.00 ➝ $185.00	High
8/10/2020	Oppenheimer	Boost Price Target		$105.00 ➝ $133.00	Medium
8/10/2020	HC Wainwright	Reiterated Rating	Buy	$163.00	Medium
8/7/2020	Credit Suisse Group	Boost Price Target	Outperform	$135.00 ➝ $140.00	Medium
8/7/2020	Barclays	Boost Price Target	Overweight	$123.00 ➝ $143.00	Medium
7/29/2020	Credit Suisse Group	Boost Price Target	Outperform	$115.00 ➝ $135.00	Medium
5/1/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$116.00	High
4/16/2020	The Goldman Sachs Group	Initiated Coverage	Buy	$151.00	High
3/30/2020	Oppenheimer	Lower Price Target	Outperform	$129.00 ➝ $105.00	High
3/12/2020	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$88.00	High
2/28/2020	HC Wainwright	Reiterated Rating	Buy	$134.00 ➝ $126.00	High
1/27/2020	BMO Capital Markets	Initiated Coverage	Market Perform	$101.00	Low
1/24/2020	HC Wainwright	Reiterated Rating	Buy	$117.00 ➝ $134.00	Medium
1/7/2020	Cowen	Reiterated Rating	Buy		High
11/5/2019	Guggenheim	Boost Price Target	Buy	$116.00 ➝ $128.00	Low
10/29/2019	Cantor Fitzgerald	Boost Price Target	Neutral	$81.00 ➝ $85.00	High
10/18/2019	Cowen	Reiterated Rating	Buy		Low
10/17/2019	HC Wainwright	Reiterated Rating	Buy		High
10/9/2019	Citigroup	Set Price Target	Buy	$130.00	Low
9/27/2019	Credit Suisse Group	Set Price Target	Positive ➝ Buy	$120.00 ➝ $115.00	Low
9/24/2019	Guggenheim	Upgrade	Neutral ➝ Buy	$116.00	High
9/11/2019	B. Riley	Lower Price Target	Neutral	$92.00 ➝ $83.00	High
9/9/2019	Cantor Fitzgerald	Lower Price Target	Neutral	$85.00 ➝ $81.00	High
9/9/2019	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$89.00 ➝ $105.00	Medium
8/6/2019	HC Wainwright	Reiterated Rating	Buy	$117.00	High
8/6/2019	Cowen	Reiterated Rating	Buy		High
8/2/2019	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$101.00 ➝ $85.00	High
7/31/2019	SVB Leerink	Set Price Target	Buy	$118.00	High
7/18/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold ➝ Hold	$86.00	Medium
7/12/2019	JPMorgan Chase & Co.	Boost Price Target	Neutral	$70.00 ➝ $101.00	Low
6/19/2019	B. Riley	Downgrade	Buy ➝ Neutral	$60.00 ➝ $92.00	Medium
6/7/2019	Guggenheim	Downgrade	Buy ➝ Neutral	$95.56	Medium
6/5/2019	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$84.00 ➝ $117.00	Low
6/5/2019	Barclays	Boost Price Target	Overweight	$85.00 ➝ $123.00	Low
6/4/2019	SunTrust Banks	Boost Price Target	Buy	$120.00	Medium
6/4/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$85.00 ➝ $125.00	Medium
6/4/2019	Cowen	Reiterated Rating	Buy		High
6/4/2019	Cantor Fitzgerald	Boost Price Target	Neutral ➝ Positive	$66.00 ➝ $85.00	High
6/4/2019	Citigroup	Upgrade	Neutral ➝ Buy	$76.00 ➝ $132.00	High
5/16/2019	Cantor Fitzgerald	Reiterated Rating	Hold		High
5/15/2019	Cowen	Reiterated Rating	Buy		High
5/1/2019	Cantor Fitzgerald	Reiterated Rating	Hold	$66.00	High
4/17/2019	JPMorgan Chase & Co.	Initiated Coverage	Neutral ➝ Neutral	$72.00	High
4/2/2019	Cantor Fitzgerald	Set Price Target	Hold	$66.00	Low
3/25/2019	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$85.00	Medium
3/19/2019	Oppenheimer	Reiterated Rating	Buy		Medium
3/13/2019	Cowen	Reiterated Rating	Buy		High
3/7/2019	Oppenheimer	Set Price Target	Buy	$81.00	Low
3/4/2019	Cantor Fitzgerald	Initiated Coverage	Neutral	$66.00	Medium
3/4/2019	Citigroup	Boost Price Target	Buy ➝ Neutral	$64.00 ➝ $77.00	Low
2/15/2019	SVB Leerink	Reiterated Rating	Outperform		High
2/15/2019	HC Wainwright	Reiterated Rating	Buy		Medium
2/15/2019	Piper Jaffray Companies	Initiated Coverage	Overweight	$85.00	Medium
1/16/2019	Oppenheimer	Boost Price Target	Outperform	$57.00 ➝ $65.00	High
11/30/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$60.00	Low
11/15/2018	Jefferies Financial Group	Reiterated Rating	Hold	$37.00	High
11/12/2018	HC Wainwright	Reiterated Rating	Buy	$65.00	High
11/11/2018	Oppenheimer	Set Price Target	Buy	$57.00	Medium
10/30/2018	Oppenheimer	Set Price Target	Buy	$62.00	Low
10/29/2018	Guggenheim	Upgrade	Neutral ➝ Buy		Low
10/22/2018	Cowen	Reiterated Rating	Buy		High
9/27/2018	Cowen	Reiterated Rating	Buy		High
9/17/2018	Guggenheim	Initiated Coverage	Neutral		Low
7/20/2018	HC Wainwright	Boost Price Target	Buy	$63.00	High
7/9/2018	Oppenheimer	Boost Price Target	Outperform	$35.00 ➝ $62.00	High
7/5/2018	Citigroup	Boost Price Target	Buy	$37.00 ➝ $64.00	Medium
6/28/2018	Cowen	Reiterated Rating	Buy		Medium
6/19/2018	SunTrust Banks	Boost Price Target	Buy	$60.00	Medium
3/12/2018	HC Wainwright	Boost Price Target	Buy	$40.00	High
3/12/2018	Barclays	Initiated Coverage	Overweight	$44.00	High
3/9/2018	SunTrust Banks	Boost Price Target	Positive ➝ Buy	$40.00	High
3/5/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $37.00	High
1/9/2018	HC Wainwright	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $21.00	N/A
1/8/2018	Oppenheimer	Set Price Target	Buy	$18.00	High
12/21/2017	Cowen	Initiated Coverage	Outperform		Low
11/22/2017	Oppenheimer	Reiterated Rating	Buy	$18.00	N/A
11/14/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $17.00	N/A
11/14/2017	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$9.00	N/A
11/7/2017	HC Wainwright	Reiterated Rating	Buy		N/A
10/12/2017	SunTrust Banks	Reiterated Rating	Buy	$13.00	N/A
10/12/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$20.00	N/A
10/2/2017	SunTrust Banks	Reiterated Rating	Buy	$13.00	High
9/19/2017	CIBC	Initiated Coverage	Outperform ➝ Outperform	$18.00	Low
9/19/2017	Citigroup	Reiterated Rating	Buy	$8.00 ➝ $16.00	Low
9/18/2017	Oppenheimer	Initiated Coverage	Outperform	$18.00	Medium
9/15/2017	SVB Leerink	Boost Price Target	Mkt Perform ➝ Market Perform	$7.00 ➝ $9.00	N/A
8/4/2017	Jefferies Financial Group	Set Price Target	Hold	$5.00	Low
6/12/2017	Jefferies Financial Group	Reiterated Rating	Hold	$4.50	Medium
4/12/2017	Jefferies Financial Group	Reiterated Rating	Hold	$5.50	High
3/11/2017	HC Wainwright	Set Price Target	Buy	$12.00 ➝ $10.00	N/A
3/11/2017	Jefferies Financial Group	Reiterated Rating	Hold	$5.00 ➝ $5.50	N/A
1/9/2017	Jefferies Financial Group	Reiterated Rating	Hold	$5.00	N/A
11/18/2016	Avondale Partners	Downgrade	Outperform ➝ Market Perform		N/A
11/17/2016	HC Wainwright	Initiated Coverage	Buy	$12.00	N/A
11/11/2016	SVB Leerink	Reiterated Rating	Hold	$7.00	N/A
11/4/2016	Wedbush	Reiterated Rating	Outperform	$12.00	N/A
10/4/2016	Wedbush	Reiterated Rating	Outperform	$12.00	N/A
8/19/2016	Piper Jaffray Companies	Reiterated Rating	Neutral		N/A
8/18/2016	Piper Jaffray Companies	Set Price Target	Hold	$7.00	N/A
8/8/2016	Piper Jaffray Companies	Reiterated Rating	Neutral	$14.00 ➝ $7.00	N/A

(Data available from 6/23/2016 forward)

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Today's Range

Now: $163.03

$161.73

$166.73

50 Day Range

MA: $158.70

$144.00

$172.04

52 Week Range

Now: $163.03

$110.17

$249.42

Volume

381,494 shs

Average Volume

474,691 shs

Market Capitalization

$8.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Frequently Asked Questions

What sell-side analysts currently cover shares of Mirati Therapeutics?

The following Wall Street analysts have issued research reports on Mirati Therapeutics in the last twelve months: Bank of America Co., Barclays PLC, BMO Capital Markets, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, CSFB, Evercore ISI, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, Oppenheimer Holdings Inc., Piper Sandler, SVB Leerink LLC, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for MRTX.

What is the current price target for Mirati Therapeutics?

13 Wall Street analysts have set twelve-month price targets for Mirati Therapeutics in the last year. Their average twelve-month price target is $217.92, suggesting a possible upside of 32.0%. Credit Suisse Group AG has the highest price target set, predicting MRTX will reach $285.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $160.00 for Mirati Therapeutics in the next year.
View the latest price targets for MRTX.

What is the current consensus analyst rating for Mirati Therapeutics?

Mirati Therapeutics currently has 1 sell rating, 4 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MRTX will outperform the market and that investors should add to their positions of Mirati Therapeutics.
View the latest ratings for MRTX.

What other companies compete with Mirati Therapeutics?

Other companies that are similar to Mirati Therapeutics include Astellas Pharma, BeiGene, Shiseido, Genmab A/S, Royalty Pharma, Takeda Pharmaceutical, Genmab A/S, MERCK Kommanditgesellschaft auf Aktien, Horizon Therapeutics Public, Alnylam Pharmaceuticals, UCB, Catalent, Viatris, Elanco Animal Health and Zai Lab.

How do I contact Mirati Therapeutics' investor relations team?

Mirati Therapeutics' physical mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is 858-332-3410 and its investor relations email address is [email protected] The official website for Mirati Therapeutics is www.mirati.com.